Recent research have demonstrated that radiotherapy is ready to induce anti-tumor immune responses along with mediating direct cytotoxic results. Cancer-associated fibroblasts (CAFs) are central constituents of the tumor stroma and take part actively in tumor immunoregulation. However, the capability of CAFs to affect immune responses within the context of radiotherapy continues to be poorly understood. This research was undertaken to find out whether or not ionizing radiation alters the CAF-mediated immunoregulatory results on pure killer (NK) cells. CAFs had been remoted from freshly resected non-small cell lung most cancers tissues, whereas NK cells had been ready from peripheral blood of wholesome donors.
Functional assays to review NK cell immune activation included proliferation charges, expression of cell floor markers, secretion of immunomodulators, cytotoxic assays, in addition to manufacturing of intracellular activation markers reminiscent of perforin and granzyme B. Our information present that CAFs inhibit NK cell activation by lowering their proliferation charges, the cytotoxic capability, the extent of degranulation, and the floor expression of stimulatory receptors, whereas concomitantly enhancing floor expression of inhibitory receptors.
Radiation delivered as single high-dose or in fractioned regimens didn’t reverse the immunosuppressive options exerted by CAFs over NK cells in vitro, regardless of triggering enhanced floor expression of a number of checkpoint ligands on irradiated CAFs. In abstract, CAFs mediate noticeable immune inhibitory results on cytokine-activated NK cells throughout co-culture in a donor-independent method. However, ionizing radiation doesn’t intervene with the CAF-mediated immunosuppressive results.
To study the cross-talk between NK cells and DCs in HCV an infection, we remoted monocytes and NK cells from 20 persistent HCV sufferers and 20 wholesome controls. Monocytes had been used to generate immature DCs which had been pulsed with HCV peptides (core, NS3-NS4 and NS5). Four totally different co-cultures had been carried out: E1: each DCs and NK cells had been from a persistent HCV affected person, E2: NK cells from a wholesome management co-cultured with DCs from a persistent HCV affected person, E3:
NK cells from a persistent HCV affected person co-cultured with DCs cells from a wholesome management and E4: each DCs and NK cells had been from a wholesome management. Using stream cytometry, we assessed the impact of those totally different co-cultures on ranges of maturation markers on DCs and ranges of activation/inhibition markers on NK cells. Results confirmed that peptide pulsed HCV DCs confirmed a maturation defect within the type of decreased HLA-DR, decreased CD86 and elevated CD83 expression particularly when co-cultured with HCV NK.
This was primarily as a result of core peptide pulsing and to a lesser extent as a result of NS5 pulsing whereas there was no impact with NS3-NS4 pulsing. Alternatively, HCV NK cells upregulated each activation and inhibition markers particularly when co-cultured with wholesome DCs. Compared to E2, E1 resulted in greater apoptosis of each NK cells and DCs with the proportion of NK apoptosis greater than that of DCs. Taken collectively, the information point out that HCV an infection impairs NK-DC cross-talk which can be a number one trigger in viral persistence and chronicity. This article is protected by copyright. All rights reserved.
Immune checkpoint molecules in pure killer cells as potential targets for most cancers immunotherapy
Recent research have demonstrated the potential of pure killer (NK) cells in immunotherapy to deal with a number of sorts of most cancers. NK cells are innate lymphoid cells that play important roles in tumor surveillance and management that effectively kill the tumor and don’t require the foremost histocompatibility complicated. The discovery of the NK’s potential as a promising therapeutic goal for most cancers is a reduction to oncologists as they face the problem of elevated chemo-resistant cancers. NK cells present nice potential towards stable and hematologic tumors and have progressively proven promise as a therapeutic goal for most cancers immunotherapy. The effector function of those cells is reliant on the steadiness of inhibitory and activating alerts.
Understanding the function of assorted immune checkpoint molecules within the exhaustion and impairment of NK cells when their inhibitory receptors are excessively expressed is especially necessary in most cancers immunotherapy research and scientific implementation. Emerging immune checkpoint receptors and molecules have been discovered to mediate NK cell dysfunction within the tumor microenvironment; this has introduced up the necessity to discover additional further NK cell-related immune checkpoints which may be exploited to reinforce the immune response to refractory cancers. Accordingly, this evaluate will give attention to the current findings in regards to the roles of immune checkpoint molecules and receptors within the regulation of NK cell operate, in addition to their potential software in tumor immunotherapy.
Natural Killer Cells in Immunotherapy: Are We Nearly There?
atural killer (NK) cells are potent anti-tumor and anti-microbial cells of our innate immune system. They are geared up with an unlimited array of receptors that acknowledge tumor cells and different pathogens. The innate immune exercise of NK cells develops sooner than the adaptive one carried out by T cells, and research counsel an necessary immunoregulatory function for every inhabitants towards the opposite.
The affiliation, noticed in acute myeloid leukemia sufferers receiving haploidentical killer-immunoglobulin-like-receptor-mismatched NK cells, with induction of full remission was the determinant to start an growing variety of scientific research administering NK cells for the therapy of most cancers sufferers. Unfortunately, though transfused NK cells demonstrated security, their noticed efficacy was poor.
![]() Alpha-bungarotoxin, CF405s |
|||
00002-100ug | Biotium | 100uG | EUR 161 |
Description: Minimum order quantity: 1 unit of 100uG |
![]() Alpha-bungarotoxin, CF680r |
|||
9-00003 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
![]() Alpha-bungarotoxin, CF680r |
|||
9-00003 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
![]() Alpha-bungarotoxin, CF640r |
|||
9-00004 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
![]() Alpha-bungarotoxin, CF640r |
|||
9-00004 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
![]() Alpha-bungarotoxin, CF488a |
|||
9-00005 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
![]() Alpha-bungarotoxin CF488a |
|||
9-00005 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
![]() Alpha-bungarotoxin, CF568 |
|||
9-00006 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
![]() Alpha-bungarotoxin, CF568 |
|||
9-00006 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
![]() Alpha-bungarotoxin, CF594 |
|||
9-00007 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
![]() Alpha-bungarotoxin CF594 |
|||
9-00007 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
![]() Alpha-bungarotoxin, CF633 |
|||
9-00009 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
![]() Alpha-bungarotoxin, CF633 |
|||
9-00009 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100uG |
![]() Alpha-bungarotoxin |
|||
00010-1 | Biotium | 1MG | EUR 168 |
Description: Minimum order quantity: 1 unit of 1MG |
![]() Fluorescein-Alpha-bungarotoxin |
|||
00011 | Biotium | 500uG | EUR 367 |
Description: Minimum order quantity: 1 unit of 500uG |
![]() Tetramethylrhodamine-Alpha-bungarotoxin |
|||
00012 | Biotium | 500uG | EUR 383 |
Description: Minimum order quantity: 1 unit of 500uG |
![]() Fluorescein-alpha-bungarotoxin: (10x50ug) |
|||
00013 | Biotium | 10ST | EUR 417 |
Description: Minimum order quantity: 1 unit of 10ST |
![]() Tetramethylrhodamine-alpha-bungarotoxin: (10x50ug) |
|||
00014 | Biotium | 10ST | EUR 466 |
Description: Minimum order quantity: 1 unit of 10ST |
![]() Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (500ug) |
|||
00015 | Biotium | 500uG | EUR 466 |
Description: Minimum order quantity: 1 unit of 500uG |
![]() Sulforhodamine 101-a-bungarotoxin (Texas Red--a-bungarotoxin): (10x50ug) |
|||
00016 | Biotium | 10ST | EUR 523 |
Description: Minimum order quantity: 1 unit of 10ST |
![]() Biotin-xx-a-bungarotoxin |
|||
00017 | Biotium | 500uG | EUR 433 |
Description: Minimum order quantity: 1 unit of 500uG |
![]() Alpha-Bungarotoxin, CF555 conjugate |
|||
9-00018 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 500uG |
![]() Alpha-Bungarotoxin, CF555 conjugate |
|||
9-00018 | Biotium |
|
|
Description: Minimum order quantity: 1 unit of 100ug |
![]() Biotin-cAMP, diisopropylethylammonium salt: |
|||
00020 | Biotium | 1MG | EUR 314 |
Description: Minimum order quantity: 1 unit of 1MG |
![]() Biotin-cAMP, diisopropylethylammonium salt: (20x50ug) |
|||
00020-1 | Biotium | 20ST | EUR 418 |
Description: Minimum order quantity: 1 unit of 20ST |
![]() Biotin-cGMP, diisopropylethylammonium salt: |
|||
00021 | Biotium | 1MG | EUR 344 |
Description: Minimum order quantity: 1 unit of 1MG |
![]() Biotin-cGMP, diisopropylethylammonium salt: (20x50ug) |
|||
00021-1 | Biotium | 20ST | EUR 448 |
Description: Minimum order quantity: 1 unit of 20ST |
![]() Cyanine 644-cAMP: |
|||
00022 | Biotium | 1MG | EUR 491 |
Description: Minimum order quantity: 1 unit of 1MG |
![]() Cyanine 644-cAMP: (20x50ug) |
|||
00022-1 | Biotium | 20ST | EUR 625 |
Description: Minimum order quantity: 1 unit of 20ST |
![]() Fluorescein Methotrexate, triammonium salt: |
|||
00023 | Biotium | 1MG | EUR 281 |
Description: Minimum order quantity: 1 unit of 1MG |
![]() Staurosporine |
|||
00025 | Biotium | 100uG | EUR 139 |
Description: Minimum order quantity: 1 unit of 100uG |
![]() Alpha-bungarotoxin, CF543 |
|||
00026 | Biotium | 500uG | EUR 494 |
Description: Minimum order quantity: 1 unit of 500uG |
![]() Rhodamine phalloidin 300u |
|||
00027 | Biotium | 300 | EUR 345 |
Description: Minimum order quantity: 1 unit of 300 |
![]() Biotin-xx-phalloidin |
|||
00028 | Biotium | 100U | EUR 428 |
Description: Minimum order quantity: 1 unit of 100U |
![]() Fluorescein-phalloidin |
|||
00030 | Biotium | 300U | EUR 345 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Rhodamine 110 phalloidin |
|||
00032 | Biotium | 300ST | EUR 345 |
Description: Minimum order quantity: 1 unit of 300ST |
![]() Sulforhodamine 101 (Texas-Red) Phalloidin |
|||
00033 | Biotium | 300EU | EUR 345 |
Description: Minimum order quantity: 1 unit of 300EU |
![]() Phalloidin, CF405M |
|||
00034 | Biotium | 300U | EUR 442 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF405M |
|||
00034-T | Biotium | 50U | EUR 133 |
Description: Minimum order quantity: 1 unit of 50U |
![]() CF488A-cAMP |
|||
00036 | Biotium | 100ug | EUR 172 |
Description: Minimum order quantity: 1 unit of 100ug |
![]() CF640R-cAMP |
|||
00037 | Biotium | 100ug | EUR 172 |
Description: Minimum order quantity: 1 unit of 100ug |
![]() Phalloidin, CF555 |
|||
00040 | Biotium | 300U | EUR 442 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF555 |
|||
00040-T | Biotium | 50U | EUR 133 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF647 |
|||
00041 | Biotium | 300U | EUR 442 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF647 |
|||
00041-T | Biotium | 50U | EUR 133 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF488A |
|||
00042 | Biotium | 300U | EUR 442 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF488A |
|||
00042-T | Biotium | 50U | EUR 133 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF543 |
|||
00043 | Biotium | 300U | EUR 442 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF543 |
|||
00043-T | Biotium | 50U | EUR 133 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF568 |
|||
00044 | Biotium | 300U | EUR 442 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF568 |
|||
00044-T | Biotium | 50U | EUR 133 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF594 |
|||
00045 | Biotium | 300U | EUR 442 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF594 |
|||
00045-T | Biotium | 50U | EUR 133 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF633 |
|||
00046 | Biotium | 300U | EUR 442 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF633 |
|||
00046-T | Biotium | 50U | EUR 133 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF660R |
|||
00047 | Biotium | 300U | EUR 442 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF660R |
|||
00047-T | Biotium | 50U | EUR 133 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF680R |
|||
00048 | Biotium | 300U | EUR 466 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF680R |
|||
00048-T | Biotium | 50U | EUR 133 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF350 |
|||
00049 | Biotium | 300U | EUR 442 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF350 |
|||
00049-T | Biotium | 50U | EUR 133 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF640R |
|||
00050 | Biotium | 300U | EUR 442 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF640R |
|||
00050-T | Biotium | 50U | EUR 133 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF532 |
|||
00051 | Biotium | 300U | EUR 442 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF532 |
|||
00051-T | Biotium | 50U | EUR 133 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF660C |
|||
00052 | Biotium | 300U | EUR 442 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF660C |
|||
00052-T | Biotium | 50U | EUR 133 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF680 |
|||
00053 | Biotium | 300U | EUR 466 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF680 |
|||
00053-T | Biotium | 50U | EUR 147 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF430 |
|||
00054 | Biotium | 300U | EUR 449 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF430 |
|||
00054-T | Biotium | 50U | EUR 139 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Phalloidin, CF440 |
|||
00055 | Biotium | 300U | EUR 449 |
Description: Minimum order quantity: 1 unit of 300U |
![]() Phalloidin, CF440 |
|||
00055-T | Biotium | 50U | EUR 139 |
Description: Minimum order quantity: 1 unit of 50U |
![]() Cholera Toxin Subunit B, CF488A conjugate |
|||
00070 | Biotium | 100ug | EUR 261 |
Description: Minimum order quantity: 1 unit of 100ug |
![]() Cholera Toxin Subunit B, CF568 conjugate |
|||
00071 | Biotium | 100ug | EUR 261 |
Description: Minimum order quantity: 1 unit of 100ug |
![]() Cholera Toxin Subunit B, CF594 conjugate |
|||
00072 | Biotium | 100ug | EUR 261 |
Description: Minimum order quantity: 1 unit of 100ug |
![]() Cholera Toxin Subunit B, CF640R conjugate |
|||
00073 | Biotium | 100ug | EUR 264 |
Description: Minimum order quantity: 1 unit of 100ug |
![]() Cholera Toxin Subunit B, CF532 conjugate |
|||
00074 | Biotium | 100ug | EUR 264 |
Description: Minimum order quantity: 1 unit of 100ug |
![]() Cholera Toxin Subunit B, CF543 conjugate |
|||
00075 | Biotium | 100ug | EUR 264 |
Description: Minimum order quantity: 1 unit of 100ug |
![]() Cholera Toxin Subunit B, CF620R conjugate |
|||
00076 | Biotium | 100ug | EUR 264 |
Description: Minimum order quantity: 1 unit of 100ug |
![]() Cholera Toxin Subunit B, CF633 conjugate |
|||
00077 | Biotium | 100ug | EUR 264 |
Description: Minimum order quantity: 1 unit of 100ug |
![]() Cholera Toxin Subunit B, CF660R conjugate |
|||
00078 | Biotium | 100ug | EUR 264 |
Description: Minimum order quantity: 1 unit of 100ug |
![]() Cholera Toxin Subunit B, CF680R conjugate |
|||
00079 | Biotium | 100ug | EUR 282 |
Description: Minimum order quantity: 1 unit of 100ug |
![]() Human Transferrin, CF488A conjugate |
|||
00081 | Biotium | 1mg | EUR 149 |
Description: Minimum order quantity: 1 unit of 1mg |
![]() Human Transferrin, CF543 conjugate |
|||
00082 | Biotium | 1mg | EUR 149 |
Description: Minimum order quantity: 1 unit of 1mg |
![]() Human Transferrin, CF568 conjugate |
|||
00083 | Biotium | 1mg | EUR 149 |
Description: Minimum order quantity: 1 unit of 1mg |
![]() Human Transferrin, CF594 conjugate |
|||
00084 | Biotium | 1mg | EUR 149 |
Description: Minimum order quantity: 1 unit of 1mg |
![]() Human Transferrin, CF640R conjugate |
|||
00085 | Biotium | 1mg | EUR 149 |
Description: Minimum order quantity: 1 unit of 1mg |
![]() Human Transferrin, CF680R conjugate |
|||
00086 | Biotium | 1mg | EUR 149 |
Description: Minimum order quantity: 1 unit of 1mg |
![]() Human Transferrin, CF750 conjugate |
|||
00087 | Biotium | 1mg | EUR 155 |
Description: Minimum order quantity: 1 unit of 1mg |
![]() HIV-1 tat recombinant antigen |
|||
00110-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HIV-1 tat recombinant antigen full length 15 kDa |
![]() HIV-1 tat recombinant antigen |
|||
00110-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HIV-1 tat recombinant antigen full length 15 kDa |
![]() HIV-1 GAG P24 Recombinant Antigen |
|||
00111-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
![]() HIV-1 GAG P24 Recombinant Antigen |
|||
00111-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HIV-1 gag p24 recombinant antigen a.a 77 to a.a 436 of the HIV-1 gag region 39 kDa |
![]() HIV-1 nef recombinant antigen |
|||
00112-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
![]() HIV-1 nef recombinant antigen |
|||
00112-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HIV-1 nef recombinant antigen a.a 3 to a.a 190 of the HIV-1 nef region 20 kDa |
![]() HIV-1 env gp41 recombinant antigen |
|||
00113-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
![]() HIV-1 env gp41 recombinant antigen |
|||
00113-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HIV-1 env gp41 recombinant antigen a.a 466 to a.a 753 of the HIV-1 env region 32 kDa |
![]() HIV-2 GP 36 Recombinant Antigen |
|||
00114-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
![]() HIV-2 GP 36 Recombinant Antigen |
|||
00114-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HIV -2 env gp36 recombinant antigen a.a 390 to a.a 702 of the HIV-2 env region 34 kDa |
![]() HCV core recombinant antigen |
|||
00115-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
![]() HCV core recombinant antigen |
|||
00115-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa |
![]() HCV core recombinant antigen, Biotin conjugate |
|||
00115-V-B-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
![]() HCV core recombinant antigen, Biotin conjugate |
|||
00115-V-B-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Biotin conjugate. |
![]() HCV core recombinant antigen, FITC conjugate |
|||
00115-V-F-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
![]() HCV core recombinant antigen, FITC conjugate |
|||
00115-V-F-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa. Fluorescein conjugate. |
![]() HCV core recombinant antigen, Rhodamine |
|||
00115-V-R-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
![]() HCV core recombinant antigen, Rhodamine |
|||
00115-V-R-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HCV core recombinant antigen a.a 2 to a.a 192 of HCV polyprotein 22 kDa . Rhodamine conjugate. |
![]() HCV NS4 recombinant antigen NS4a+b |
|||
00116-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
![]() HCV NS4 recombinant antigen NS4a+b |
|||
00116-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. |
![]() HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
00116-V-B-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
![]() HCV NS4 recombinant antigen NS4a+b, Biotin |
|||
00116-V-B-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Biotin conjugate. |
![]() HCV NS4 recombinant antigen NS4a+b, FITC |
|||
00116-V-F-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
![]() HCV NS4 recombinant antigen NS4a+b, FITC |
|||
00116-V-F-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Fluorescein conjugate. |
![]() HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
00116-V-R-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
![]() HCV NS4 recombinant antigen NS4a+b, Rhodamine |
|||
00116-V-R-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HCV NS4 recombinant antigen NS4a+b a.a 1658 to a.a 1863 of HCV polyprotein, 19 kDa. Rhodamine conjugate. |
![]() HCV NS3 recombinant antigen |
|||
00117-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
![]() HCV NS3 recombinant antigen |
|||
00117-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HCV NS3 recombinant antigen a.a 1400 to a.a 1643 of HCV polyprotein 22 kDa |
![]() HBV core recombinant antigen |
|||
00120-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
![]() HBV core recombinant antigen |
|||
00120-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 183 of HBV core antigen 18 kDa |
![]() HBV core recombinant antigen, Delta |
|||
00121-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
![]() HBV core recombinant antigen, Delta |
|||
00121-V-1000ug | Virogen | 1000 ug | EUR 1282.5 |
Description: HBV core recombinant antigen HBcAg a.a 1 to a.a 144 of HBV core antigen 16 kDa |
![]() HBV surface recombinant antigen HBsAg |
|||
00122-V-01mg | Virogen | 0,1 mg | EUR 267.5 |
Description: HBV surface recombinant antigen HBsAg antigen 22 kDa Pichia pastoris recombinant |
In current years, novel research have emerged, combining NK cells with different immunotherapeutic brokers, reminiscent of monoclonal antibodies, which could enhance scientific efficacy. Moreover, genetically-modified NK cells aimed toward arming NK cells with higher efficacy and persistence have appeared as another choice. Here, we evaluate novel pre-clinical and scientific research printed within the final 5 years administering NK cells as a monotherapy and mixed with different brokers, and we additionally evaluate chimeric antigen receptor-modified NK cells for the therapy of most cancers sufferers.